Effectiveness of Tofacitinib in Patients With Ulcerative Colitis: A Nationwide Veterans Administration Cohort Study

Nabeel Khan; Ramaswamy Sundararajan; Manthankumar Patel; Chinmay Trivedi; Yu-Xiao Yang

doi:10.14309/ajg.0000000000002761

Effectiveness of Tofacitinib in Patients With Ulcerative Colitis: A Nationwide Veterans Administration Cohort Study

Am J Gastroenterol. 2024 Apr 5. doi: 10.14309/ajg.0000000000002761. Online ahead of print.

Authors

Nabeel Khan^{1

2}, Ramaswamy Sundararajan¹, Manthankumar Patel¹, Chinmay Trivedi¹, Yu-Xiao Yang^{1

2

3}

Affiliations

¹ Department of Gastroenterology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA.
² Division of Gastroenterology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
³ Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA .

PMID: 38483302
DOI: 10.14309/ajg.0000000000002761

Abstract

Introduction: There is paucity of data on the effectiveness and safety of tofacitinib among elderly patients with ulcerative colitis (UC).

Methods: Through a retrospective cohort study among the US National Veterans Affairs Healthcare System, we evaluated effectiveness among the elderly (≥65) and young (<65) patients with UC initiated on tofacitinib.

Results: Among 158 patients (53 elderly, 105 young), effectiveness at 12 months was 50.94% in the elderly and 33.33% in the young ( P = 0.032).

Discussion: In a nationwide cohort of patients with UC initiating tofacitinib, effectiveness was seen in half of the elderly patients.

Grants and funding

Pfizer